Recurrent Aphthous Stomatitis: Etiology and Clinical Management

Recurrent aphthous stomatitis, commonly known as canker sores, is the most frequent ulcerative disease of the oral mucosa, affecting an estimated 20% of the general population. The condition is characterized by recurrent, painful ulcers on the non-keratinized mucosa that resolve s...

Recurrent aphthous stomatitis, commonly known as canker sores, is the most frequent ulcerative disease of the oral mucosa, affecting an estimated 20% of the general population. The condition is characterized by recurrent, painful ulcers on the non-keratinized mucosa that resolve spontaneously only to reappear. This article reviews the etiology of aphthous ulcers, their clinical subtypes, and the practical steps used to manage them.

What Is Recurrent Aphthous Stomatitis?

Recurrent aphthous stomatitis (RAS) is an inflammatory condition of unknown but multifactorial origin that produces well-defined, painful ulcers on the buccal and labial mucosa, the floor of the mouth, and the ventral surface of the tongue. The ulcers are typically covered by a grey or yellow pseudomembrane surrounded by an erythematous halo, and they heal without scarring except in the most severe forms.

The condition is distinct from herpes simplex infection. Aphthous ulcers are usually solitary or few in number, occur on non-keratinized mucosa, and are not preceded by vesicles, whereas herpetic lesions appear as clusters of vesicles on keratinized mucosa. Recognizing this distinction matters because the management of the two conditions is completely different.

Etiology and Predisposing Factors

The exact cause of RAS remains unknown, but a strong genetic predisposition and an abnormal local immune response are thought to underlie the disorder. The immune reaction, driven largely by T cells, appears to be triggered by a range of local and systemic factors in susceptible individuals.

It is important to recognize that RAS is a diagnosis of exclusion. When aphthous-like ulcers are accompanied by systemic symptoms such as fever, skin lesions, or gastrointestinal complaints, the clinician should consider systemic conditions including Behcet disease, inflammatory bowel disease, and celiac disease.

Classification of Aphthous Ulcers

Aphthous ulcers are divided into three clinical types based on size, number, and distribution. Distinguishing them is clinically relevant because the subtypes differ in severity, healing time, and the likelihood of scarring.

Minor aphthous ulcers are by far the most common and account for about 80% of cases. Major aphthous ulcers are larger, deeper, slower to heal, and frequently scar, while herpetiform ulcers resemble herpetic lesions as clusters of tiny ulcers that may coalesce, despite having no viral cause.

Diagnosis

The diagnosis of RAS is clinical, based on the history of recurrence and the characteristic appearance and distribution of the ulcers. No laboratory test confirms the diagnosis, and biopsy is rarely needed unless a lesion is atypical, persistent, or suggestive of another disease. The key diagnostic question is whether the presentation fits the pattern of recurrent, self-limiting, painful ulcers on non-keratinized mucosa.

The following features should prompt further investigation rather than a diagnosis of simple RAS:

- Ulcers that persist for more than three weeks without healing

- Ulcers that begin after the age of 30 with no previous history

- Systemic symptoms, including fever, rash, joint pain, or diarrhea

- Genital ulceration or ocular inflammation, suggesting Behcet disease

- Poor response to standard topical therapy

Management

Symptomatic Relief

The goals of treatment are to reduce pain, shorten healing time, and reduce the frequency of recurrence. For mild, infrequent ulcers, simple measures may suffice, including avoiding known triggers, maintaining a soft diet, and using over-the-counter protective pastes and rinses.

Topical Pharmacotherapy

Topical corticosteroids are the mainstay of treatment for patients with frequent or painful ulcers. They suppress the local inflammatory response and shorten healing time when applied early in the course of an ulcer. Commonly used preparations include triamcinolone acetonide in an adhesive paste, beclomethasone, and fluticasone sprays. Additional options include topical analgesics, such as lidocaine, and antimicrobial mouth rinses such as chlorhexidine.

Systemic Therapy

Patients with severe, frequent, or refractory aphthous ulceration may require systemic treatment, but this is reserved for specialist care because of the risk of side effects. Options include colchicine, dapsone, pentoxifylline, and short courses of systemic corticosteroids. Nutritional supplements are added when testing confirms an underlying deficiency of iron, folate, or vitamin B12, since correcting such deficiencies can markedly reduce recurrence.

Prognosis

The severity of RAS varies greatly between individuals. Many patients experience only occasional mild ulcers that resolve within two weeks and respond well to symptomatic care. A smaller group suffers severe, frequent, or major ulcers that interfere with eating, speaking, and quality of life. Although the condition is not curable, most patients achieve good control with a combination of trigger avoidance, topical therapy, and, where appropriate, systemic agents under specialist guidance.

Clinical Key Points

- RAS is the most common oral ulcerative disease and is characterized by recurrent, self-limiting, painful ulcers on non-keratinized mucosa.

- The three subtypes, minor, major, and herpetiform, differ in size, healing, and scarring.

- RAS is a diagnosis of exclusion; persistent, late-onset, or systemic presentations require investigation.

- Topical corticosteroids are the first-line therapy for frequent and painful ulcers.

- Nutritional deficiency, stress, and trauma are common modifiable triggers worth addressing.

Conclusion

Recurrent aphthous stomatitis is a common, painful, and recurring condition with a multifactorial etiology centered on genetic susceptibility and abnormal mucosal immunity. Classification into minor, major, and herpetiform types guides expectations about healing and scarring, while diagnosis requires the exclusion of systemic disease. Management is largely symptomatic, combining trigger avoidance, topical anesthetics, and topical corticosteroids, with systemic therapy reserved for severe cases. With a structured and individualized approach, most patients can achieve meaningful relief and a better quality of life.